ADELAIDE, Australia, June 27, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central
Bionomics Investor Webinar
June 13, 2022
ADELAIDE, Australia, June 13, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO |Nasdaq: BNOX ), ( Bionomics or the Company ), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central
ADELAIDE, Australia, May 16, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous
Bionomics' Half-Year Report
February 23, 2022
ADELAIDE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), today announced its half-year report for the half-year ended 31 December 2021. The half-year ending 31 December 2021 represented a transformational period for Bionomics in which the Company made great
EASTWOOD, Australia, Jan. 14, 2022 /PRNewswire/ -- Bionomics Limited (Nasdaq: BNOX , ASX: BNO), a clinical-stage biopharmaceutical developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet
ADELAIDE, Australia , Jan. 12, 2022 /PRNewswire/ -- Bionomics Limited (ASX:BNO,NASDAQ: BNOX ) (Bionomics or Company), a clinical-stage biopharmaceutical company, participated in the H.C Wainwright BioConnect Conference that was held virtually from January 10-13, 2022 .
EASTWOOD, Australia, Jan. 5, 2022 /PRNewswire/ -- Bionomics Limited ( Bionomics or Company ), a clinical-stage biopharmaceutical company, today announced the issuance of 243,300 American Depositary Shares ( ADSs ), each representing 180 ordinary shares of Bionomics, pursuant to the exercise in
EASTWOOD, Australia, Jan. 3, 2022 /PRNewswire/ -- Bionomics Limited (ASX: BNO,NASDAQ: BNOX ) ( Bionomics or Company ), a clinical-stage biopharmaceutical company, is pleased to announce that it has initiated its Phase 2 clinical trial (the PREVAIL Study) to evaluate BNC210 for the acute